PACB - Latest News

Pacific Biosciences of California, Inc. (PACB), operates in Healthcare / Medical - Devices, trades on NASDAQ.

Market capitalization stands near $357.2M. Beta to the broader market is 2.32.

The article list below shows the most recent PACB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PACB Headlines

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity

marketbeat.com - Aug 16, 2026

Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 milli

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

zacks.com - Aug 6, 2026

PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.

Pacific Biosciences: It's Only Getting Worse

seekingalpha.com - Aug 6, 2026

Pacific Biosciences reported Q2 revenues of $39. 01 million, missing estimates and guiding 2026 revenues down, below consensus.

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

seekingalpha.com - Aug 6, 2026

Pacific Biosciences of California, Inc.

Pacific Biosciences of California Q2 Earnings Call Highlights

marketbeat.com - Aug 6, 2026

Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million, roughly flat from $39. 8 million a year earlier, w

How News Affects PACB Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PACB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PACB news questions

What is the latest PACB news headline?

The most recent PACB headline (Aug 16, 2026) is "PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PACB news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PACB news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PACB options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.